IGHE and asthma: The humanized anti-IgE antibody omalizumab has been confirmed to improve the asthma symptom score, reduce the chances of acute asthma attacks, reduce the dosage of oral or inhaled glucocorticoid, and improve the quality of life of patients with asthma.